Success of the Orphan Drug Act has brought with it pushback from payers, policymakers, and legislators. Pushback may be warranted in some instances. But, a case-by-case approach examining the value of orphan products, independent of their orphan status, is a more appropriate general policy.
Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?
